Paul Brennan, 生物制药老兵, 准备领导Microbio Ltd, 快速败血症检测技术的开发商。 Paul Brennan, biopharmaceutical veteran, set to lead Microbio Ltd, developer of rapid sepsis detection tech.

澳大利亚一家诊断公司Microbio有限公司已任命Paul Brennan于2024年12月2日担任董事会新主席。 Microbio Ltd, an Australian diagnostics firm, has appointed Paul Brennan as its new Board Chair on December 2, 2024. Brennan拥有超过35年的生物制药经验, 目前是 Immuron 的非执行主席。 Brennan, with over 35 years of biopharmaceutical experience, is currently Immuron's non-executive chair. 微生物的重点是其感染性IDTM BSI产品,该产品在三小时内检测出26种病原体,与94%以上的败血病菌有关,目的是成为败血症检测标准。 Microbio is focusing on its InfectID™ BSI product, which detects 26 pathogens linked to over 94% of sepsis cases in under three hours, aiming to become the standard for sepsis detection.